Full Text View
Tabular View
No Study Results Posted
Related Studies
Bowel Preparation and Prokinetics in Capsule Endoscopy
This study is currently recruiting participants.
Study NCT00275184   Information provided by North West London Hospitals NHS Trust
First Received: January 10, 2006   Last Updated: September 21, 2007   History of Changes

January 10, 2006
September 21, 2007
January 2006
 
Quality of capsule endoscopic images, stomach and small bowel transit times and capsule completion rates to the end of the small bowel
Same as current
Complete list of historical versions of study NCT00275184 on ClinicalTrials.gov Archive Site
The tolerance of the bowel preparation to indicate future usage
The tolerance of the bowel preparation to indicate future usage.
 
Bowel Preparation and Prokinetics in Capsule Endoscopy
A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide

The aim of this study is to determine whether taking bowel preparation (citramag and senna) or a medicine to speed up transit through the stomach (metoclopramide), will improve the quality of the images seen, increase the transit through the small bowel, and increase the rate of completion of capsule endoscopy.

The secondary objective is to determine whether patients could routinely tolerate this bowel preparation prior to capsule endoscopy and whether the diagnostic yield of capsule endoscopy is improved.

Capsule endoscopy is a diagnostic tool for the detection of small bowel disease allowing noninvasive endoscopic examination of the entire small bowel without the need for sedation. Its limited battery life of 8+/-1 hours means it is paramount that the Capsule reaches the caecum, visualizing the whole of the small intestine, and also that the mucosal views obtained are clear, facilitating detection of pathologic lesions.

So far no optimal protocol for bowel preparation prior to Capsule endoscopy has been established. Recently, several studies have shown that bowel preparation with polyethylene glycol significantly reduces both gastric and small bowel transit times. Similarly, visualization of the small intestine and therefore 'diagnostic yield' have both been shown to be improved by both sodium phosphate and polyethylene glycol preparation. A more recent study by Selby et al also demonstrates that the prokinetic agent metoclopramide (which is known to promote emptying of the stomach) reduced both stomach and small bowel transit time, increasing completion rates from 76% to 97%).

The proposal is to perform a randomised, controlled study using Citramag and Senna bowel preparation or Metoclopramide to determine whether test completion rates are improved and whether the images of the bowel are of better quality.

The hypothesis is that the improved wall visibility and increased completion rates will improve the diagnostic yield of Capsule endoscopy and therefore improve patient care.

Phase III
Interventional
Diagnostic, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
  • Small Bowel Disease
  • Gastrointestinal Hemorrhage
  • Refractory Anemia
  • Drug: Senna
  • Drug: Citramag powder
  • Drug: Metoclopramide
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
150
 
 

Inclusion Criteria:

  • Patients over 18 who have been referred for capsule endoscopy

Exclusion Criteria:

  • Under 18
  • Known or suspected gastrointestinal tract obstruction as this may impede passage of the capsule
  • Known small bowel stricture or fistula as this may impede capsule passage
  • Pregnancy, breast feeding or phaeochromocytoma as metoclopramide is contraindicated
  • Recent gastrointestinal surgery in view of the risk of impeded capsule passage
  • Permanent cardiac pacemaker or implantable defibrillator in-situ to avoid the risk of possible interference
  • Congestive cardiac failure as citramag is contraindicated in such patients
Both
18 Years and older
No
Contact: Christopher Fraser, MB BCH, MD, FRCP chris.fraser@imperial.ac.uk
Contact: Neil Patterson, MB BCH, MD, MRCP neil@rnpaterson.idps.co.uk
United Kingdom
 
NCT00275184
 
05/CE/94, REC 05/Q0405/94, EudraCT No: 2005-004423-19
North West London Hospitals NHS Trust
 
Principal Investigator: Christopher Fraser, MB BCH, MD, FRCP St Mark's Hospital, North West London Hospitals NHS Trust
North West London Hospitals NHS Trust
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP